


MiYOSMART



**Myopia control effect
sustained over 6 years**



For over 60 years, HOYA Vision Care has been a passionate and global leader in optical technology innovation. As a manufacturer of high-quality, high-performing eyeglass lenses, HOYA continues to drive optical technology innovation to find the best vision care solutions for Eye Care Professionals.

By: Kim Kochendorfer, RO



HOYA's MiYOSMART lenses: a safe, effective, and non-invasive solution for myopia control

The Canadian Association of Optometrists (CAO) recognizes that myopia, and in particular high myopia, is a global public health issue and cannot be considered merely an inconvenience of uncorrected vision. There is no "safe" level of myopia, given that all levels of myopia have an accompanying increased risk of eye disease¹. The CAO supports the position of the World Council of Optometry and endorses evidence-based myopia management as a standard of care for all at-risk patients².

MiYOSMART is reported as an effective myopia management option by the International Myopia Institute³.

Clear vision for the future

In response to myopia prevalence reaching new heights in several countries, and after years of development and key clinical trials, HOYA's effective myopia management method is ready to provide practitioners, parents and patients alike with clearer vision for the future. The innovative MiYOSMART ophthalmic lens has been developed by The Hong Kong Polytechnic University and HOYA, who partnered together to create an easy-to-prescribe lens that is aesthetically pleasing with the look of a standard single vision lens.

HOYA MiYOSMART ophthalmic lens corrects the myopic refractive error and improves the distance vision and at the same time provides peripheral relative plus power for creating peripheral myopic defocus. A two-year randomized trial presented promising results, showing on average, a reduction in myopia progression by 60%⁴ in children 8-13 years old. This has since been reinforced by 3 and 6-year follow-up studies that showed the slowdown was sustained⁵. The 6-year follow-up found the average cumulative myopia progression less than -1.00D over 6 years, and children who stopped wearing MiYOSMART ophthalmic lens showed no rebound effect, no acceleration in axial length growth compared to the axial length growth in "age-normative" non-treated myopic children⁶.

This revolutionary ophthalmic lens makes use of the patent-protected Defocus Incorporated Multiple Segments (D.I.M.S.) Technology⁷ contains a 9.4mm central zone and a 33mm peripheral treatment area, known as the treatment zone, which consists of micro-segments of +3.50 diopters, arranged in a honeycomb structure. The unique design preserves a 50:50 ratio of full prescription to defocus, without dependence on pupil size.

The technology itself has taken the ophthalmic world by storm, winning the Gold Prize, Grand Award & Special Gold Award at the International Exhibition of Interventions of Geneva, Switzerland 2018. More recently, it also won the Silmo d'Or Award in the Vision category at the Silmo Paris Optical Fair 2020.





Technology aside, the MiYOSMART lens offers the wearer a more comfortable solution and parents peace of mind. Compared to the contact lens treatments, there are no handling or hygiene issues associated with MiYOSMART, adding an extra layer of comfort and safety for the wearer. The lenses themselves are lightweight, impact resistant and offer 100% UV protection, and come with an anti-reflective coating that provides added scratch resistance and enhances the performance and cosmetics of the lens.

Early treatment is critical in reducing the progression of short-sightedness and mitigating the rising global threat of myopia. MiYOSMART is trusted and proven. Over 2 million MiYOSMART ophthalmic lenses have been purchased by parents across the world.⁸ Combined with regular check-ups and natural methods, such as reduced screen time, together, we now have an opportunity to work towards a clearer future for all.

References

1. Flitcroft DI. The complex interactions of retinal, optical and environmental factors in myopia aetiology. *Prog Retin Eye Res.* 2012;31(6):622-60.
2. <https://opto.ca/sites/default/files/resources/documents/CAO%20Position%20Statement%20on%20Myopia%20Management%202022.pdf>
3. Jong M, Jonas JB, Wolffsohn JS, et al. IMI 2021 Yearly Digest. *Invest. Ophthalmol. Vis. Sci.* 2021;62(5):7. <https://doi.org/10.1167/iops.62.5.7>
4. Lam CSY, Tang WC, Tse DY, Lee RPK, Chun RKM, Hasegawa K, Qi H, Hatanaka T, To CH. Defocus Incorporated Multiple Segments (DIMS) spectacle lenses slow myopia progression: a 2-year randomized clinical trial. *British Journal of Ophthalmology*. Published Online First: 29 May 2019. doi: 10.1136/bjophthalmol-2018-313739 <https://bjo.bmj.com/content/104/3/363>
5. Lam CS, Tang WC, Lee PH, et al. Myopia control effect of defocus incorporated multiple segments (DIMS) spectacle lens in Chinese children: results of a 3-year follow-up study. *British Journal of Ophthalmology* Published Online First: 17 March 2021. doi: 10.1136/bjophthalmol-2020-317664 <https://bjo.bmj.com/content/early/2021/03/17/bjophthalmol-2020-317664>
6. Lam CS, et al. Myopia control in children wearing DIMS spectacle lens: 6 years results. *Invest Ophthalmol Vis Sci.* 2022;63:ARVO E-Abstract 4247
7. Patent protected in China under patent number ZL 201310628174.8 , in Hong Kong under patent number 1210838, in US under patent number 10268050 & 11029540
8. Based on number of MiYOSMART lenses sold per HOYA sales data on file as of June 2022.

PRODUCT DISCLAIMER HOYA MiYOSMART has not been approved for myopia management in all countries, including the U.S., and is not currently available for sale in all countries, including the U.S.

